Instruction 1(b).

## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     STAHL NEIL						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [ REGN ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify					
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 05/10/2013								SVP Research and Development S					
(Street) TARRYTOWN NY 10591					4. 	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Inc Line)									ividual or Joint/Group Filing (Check Applica Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)								22.42		4 Di		a oficio							
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)					saction	2/ Ex	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 au			5. Amount of		s lly ollowing	Form (D) or	: Direct I r Indirect I str. 4)	. Nature of ndirect eneficial ownership nstr. 4)
									Code	v	Amount	(A) or (D)	Price		Transacti (Instr. 3 a			<u> </u>	
Common Stock					05/10/2013						55,438	A	\$21.9	92	104	104,426		D	
Common Stock 09					0/2013	3			F		4,527	D	\$268	.4	99,899		D		
Common Stock 05/10					0/2013	3			F		27,873	D	\$268	.4	72,	72,026		D	
Common Stock 05/13/					3/2013	.013			S		13,378	D	\$276.7	'1 <sup>(1)</sup>	58,	58,648		D	
Common Stock 05/13/20					3/2013	013			S		9,660	D	\$277.1	<b>2</b> <sup>(2)</sup>	48,	48,988		D	
Common Stock															5,536			I	By 401(k) Plan
			Table II								oosed of, convertib			y Oı	wned				*
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code ( 8)				6. Date Exer Expiration D (Month/Day/		ate	7. Title ar of Securi Underlyir Derivativ (Instr. 3 a	ties ng e Securit	Der Sec	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A) (D)		Date Exercisable		Expiration Date	Title	Amour or Number of Shares	er		Transaction(s) (Instr. 4)			
Non- Qualified Stock Option (right to buy)	\$21.92	05/10/2013						55,438	(3)		12/17/2017	Common Stock	55,43	8	(4)	0		D	
Non- Qualified Stock Option (right to buy)	\$268.4	05/10/2013			A		4,527		11/10	/2013	05/10/2023	Common Stock	4,527	7	(4)	4,527	7	D	

## **Explanation of Responses:**

- 1. Represents volume-weighted average price of sales of 13,378 shares of Company stock on May 13, 2013 at prices ranging from \$276.00 to \$276.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 13, 2013 at each separate price.
- 2. Represents volume-weighted average price of sales of 9,660 shares of Company stock on May 13, 2013 at prices ranging from \$277.00 to \$277.9. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 13, 2013 at each separate price.
- 3. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- 4. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case

.s.\*\*Neil Stahl

05/14/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.